OREANDA-NEWS Scientists from the Institute of Biomedical Sciences at the University of Georgia (USA) have created a drug from lipid nanoparticles for the prevention of intestinal cancer associated with colitis. The results of the study are published in the journal Pharmaceuticals.

The preparation consists of nanoliposomes to which M13 (M13-NL) — lipid nanoparticles are attached. Previous work in laboratory cultures (in vitro) has shown that M13-NL effectively affects the colon and changes the gut microbiome. In addition, the substance is able to modify the metabolites of microorganisms that can prevent the development of chronic ulcerative colitis.

Now experts have decided to test the drug on living organisms, as well as to find out whether it can resist the development of intestinal cancer provoked by colitis. Mice given M13-NL did not develop tumors. Now the authors want to conduct additional tests to prove that the drug can be used in humans.

In August, the staff of the Garvan Institute of Medical Research presented a drug against one of the most dangerous types of cancer — pancreatic adenocarcinoma. Usually, within five years after diagnosis, more than ten percent of patients survive.